SOPHiA GENETICS technology helps advance
cancer research across India
SOPHiA GENETICS and Karkinos Healthcare join
forces to propel cutting-edge genomic solutions for breakthroughs
in personalized cancer care in India
BOSTON and ROLLE,
Switzerland, Jan. 14, 2024 /PRNewswire/ -- SOPHiA
GENETICS (Nasdaq: SOPH), a cloud-native software company and a
leader in data-driven medicine, today announced that Karkinos
Healthcare, a purpose-driven cancer care technology network based
in India, will partner with SOPHiA
GENETICS and adopt the SOPHiA DDM™ Platform to advance cancer
testing and research for blood cancers and solid tumors to
underserved areas in low and middle-income countries.
Karkinos Healthcare is a purpose-driven, technology-led oncology
platform, focused on early detection, advanced diagnostics, and
treatment delivery of common cancers, using its Distributed Cancer
Care Network across India.
Karkinos Healthcare provides end-to-end solutions for oncology
ecosystem, including disease screening, diagnosis, surgery,
chemotherapy, radiotherapy and comprehensive patient
navigation through the care continuum, in addition to operating
advanced research and development laboratories. The company is on a
mission to create 'Community as a Cancer Centre' with an endeavour
to serve one million patients annually by addressing the
accessibility and affordability gaps in cancer care through a
digitally curated hub and spoke and further spoke model, and not
restrict cancer care to comprehensive centres alone.
"It is our continued goal to improve health outcomes for
patients globally by expanding access to precision oncology and
equipping local health institutions with the tools and technology
needed to practice data-driven medicine," said Dr. Jurgi
Camblong, CEO and Co-founder, SOPHiA GENETICS. "By aligning
with Karkinos, who share the mutual goal, we can help increase the
use of best-in-class cancer testing for rural and underserved
communities around the world."
On this strategic partnership, Dr. R Venkataramanan, Founder
and CEO, Karkinos Healthcare said, "Through collaborative
research initiatives, Karkinos Healthcare aims to address the
comprehensive genomic landscape identification for Indian
population, with a focus on precision medicine. This alliance will
have the potential to generate evidence and world-class research
for faster and accurate diagnosis and better control and management
of cancers, particularly for the underprivileged population of our
country."
The SOPHiA DDM™ Platform is designed to compute a wide array of
genomic variants and continually hone machine learning algorithms
to detect rare and challenging cases. Karkinos Healthcare will use
SOPHiA GENETICS' technology to expand its offerings, advance
research and streamline workflow for a variety of blood cancers,
including Myeloid cancer and Lymphoma. In addition, the company
will analyse solid tumours for a variety of cancer types including
ovarian, prostate, breast, pancreas, lung, colorectal, skin, and
brain cancers.
The SOPHiA DDM™ Platform offers tailored NGS-based workflows to
streamline processes – from sample to report – to accelerate
analysis. By using the SOPHiA DDM™ Platform, researchers from
Karkinos Healthcare will quickly obtain high-quality and
reproducible data that will ultimately accelerate clinical research
studies and advance the use of precision medicine.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a software company dedicated to
establishing the practice of data-driven medicine as the standard
of care and for life sciences research. It is the creator of the
SOPHiA DDM™ Platform, a cloud-native platform capable of analyzing
data and generating insights from complex multimodal data sets and
different diagnostic modalities. The SOPHiA DDM™ Platform and
related solutions, products and services are currently used by a
broad network of hospital, laboratory, and biopharma institutions
globally. For more information, visit SOPHiAGENETICS.COM, or
connect on X, LinkedIn, Facebook,
and Instagram. Where others see data, we see
answers.
Product Disclaimer
SOPHiA GENETICS products
are for Research Use Only and not for use in diagnostic procedures,
unless specified otherwise. The information in this press release
is about products that may or may not be available in different
countries and, if applicable, may or may not have received approval
or market clearance by a governmental regulatory body for
different indications for use. Please contact
support@sophiagenetics.com to obtain the appropriate product
information for your country of residence.
SOPHiA GENETICS: Forward-Looking
Statement
This press release contains statements that
constitute forward-looking statements. All statements other than
statements of historical facts contained in this press release,
including statements regarding our future results of operations and
financial position, business strategy, products, and technology, as
well as plans and objectives of management for future operations,
are forward-looking statements. Forward-looking statements are
based on our management's beliefs and assumptions and on
information currently available to our management. Such statements
are subject to risks and uncertainties, and actual results may
differ materially from those expressed or implied in the
forward-looking statements due to various factors, including those
described in our filings with the U.S. Securities and Exchange
Commission. No assurance can be given that such future results will
be achieved. Such forward-looking statements contained in this
press release speak only as of the date hereof. We expressly
disclaim any obligation or undertaking to update these
forward-looking statements contained in this press release to
reflect any change in our expectations or any change in events,
conditions, or circumstances on which such statements are based,
unless required to do so by applicable law. No representations or
warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
About Karkinos Healthcare
Karkinos Healthcare is a
purpose driven technology-led oncology health care platform
for early detection and diagnosis of common cancers. The
organisation espouses use of a distributed cancer care
network, while working with a network of healthcare
institutions and domain experts within the ecosystem, with an aim
to provide comprehensive cancer care closer to individuals'
homes.
Tata Group, Reliance Industries, Mayo Clinic, and Rakuten
Medical Inc. are among the World's leading organizations that have
invested in Karkinos Healthcare. The company has also partnered
with Tata Memorial Hospital, Guys and St Thomas NHS Foundation
Trust (UK), and has inked several research collaborations with
leading academic institutions in the
United States to stay on the cutting edge of oncology
treatment and care. To learn more, visit
https://www.karkinos.in/about-us/
Logo -
https://mma.prnewswire.com/media/1673202/4493685/SOPHiA_GENETICS_Logo.jpg
View original
content:https://www.prnewswire.co.uk/news-releases/sophia-genetics-and-karkinos-healthcare-forge-strategic-partnership-to-advance-cancer-research-in-india-302034184.html